| アブストラクト | Drug induced liver injury (DILI) is one of the key safety concerns in drug development. To assess the likelihood of drug candidates with potential adverse reactions of liver, we propose a compound attributes-based approach to predicting hepatobiliary disorders that are routinely reported to US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Specifically, we developed a support vector machine (SVM) model with recursive feature extraction, based on physicochemical and structural properties of compounds as model input. Cross validation demonstrates that the predictive model has a robust performance with averaged 70% of both sensitivity and specificity over 500 trials. An independent validation was performed on public benchmark drugs and the results suggest potential utility of our model for identifying safety alerts. This in silico approach, upon further validation, would ultimately be implemented, together with other in vitro safety assays, for screening compounds early in drug development. |
|---|
| ジャーナル名 | PloS one |
|---|
| Pubmed追加日 | 2020/4/16 |
|---|
| 投稿者 | Liu, Yang; Gao, Hua; He, Yudong D |
|---|
| 組織名 | Genome Analysis Unit, Amgen Research, Amgen Inc., South San Francisco,;California, United States of America.;Molecular Engineering, Amgen Research, Amgen Inc., Cambridge, Massachusetts,;United States of America. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32294131/ |
|---|
